Loading stock data…
NTRA
$196.91+1.59 (+0.81%)
Pre-Market$196.00-0.91 (-0.46%)· Last close May 14
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Natera, Inc. in the Healthcare sector is trading at $196.91. Wall Street consensus targets $260.22 (18 analysts), implying a +32.2% move over the next 12 months. The stock is currently 23% below its 52-week high of $256.36, remaining 1.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +32.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$196.91
Potential Downside
0%
Whystock Fair Value$196.91
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Mean target$260.22+32.2%
Range$190.00 – $300.00
Fundamentals
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of tre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.79%
Volume
Today's trading volume
1.38M
Recent News
The Cancer Test That Wall Street Is Betting On
Much of the public debate over cancer blood tests has focused on early detection products like the Galleri test from a company called Grail which promises to screen healthy people for more than 50 types of cancer. While these tests capture headlines and Super Bowl ads, the more proven opportunity for investors has been in a less glamorous market: checking for cancer recurrence. For a patient who has just had a tumor surgically removed, the critical question is whether every cancer cell is gone.
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report
The quarterly results for Natera, Inc. ( NASDAQ:NTRA ) were released last week, making it a good time to revisit its...
Why Natera (NTRA) Shares Are Plunging Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 12.2% in the afternoon session after the company reported mixed first-quarter 2026 financial results, where strong revenue growth was overshadowed by a wider-than-expected net loss.
NTRA Q1 Deep Dive: Robust Volume Growth and Product Expansion Shape Outlook
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 38.8% year on year to $696.6 million. Its GAAP loss of $0.60 per share was 8.4% below analysts’ consensus estimates.
Assessing Natera (NTRA) Valuation After Recent Share Price Pullback And Long Term Returns
Natera (NTRA) is back in focus after recent trading, with the stock closing at US$194.24 and showing mixed performance over the past week, month and past three months for investors tracking its moves. See our latest analysis for Natera. The recent 1 day share price drop of 11.64% has pulled Natera’s year to date share price return down 15.12%, although its 1 year total shareholder return of 23.49% and 3 year total shareholder return above 2x still signal strong longer term momentum. If...